RBC Upgrades Rigel Pharmaceuticals (RIGL) to Sector Perform
More News related to RIGL
- Eleven Rigel Product Candidate Presentations at 2009 ASH Meeting
- Morning Movers 11/23: ABIO, SEED, FIF, FNET, DDRX, JOBS Higher; BBI, CGA, BOFL, CEPH Lower
- RBC Upgrades Rigel Pharmaceuticals (RIGL) to Outperform
- Rigel Announces Third Quarter 2009 Financial Results
- Rigel Announces Presentations at Two Investor Conferences
More News related to Upgrades
- Oppenheimer Issues Intraday Upgrade on Comcast (CMCSA)
- Canaccord Adams Upgrades Open Text (OTEX) to Buy; Raises Estimates & PT
- Stephens & Co Upgrades Aeropostale (ARO) to Overweight
- McAdams Wright Ragen Upgrades Zumiez (ZUMZ) to Buy
- Dahlman Rose Upgrades Intrepid Potash (IPI) to Hold
RBC upgrades Rigel Pharmaceuticals (Nasdaq: RIGL) from Underperform to Sector Perform.
Rigel Pharmaceuticals, Inc. (Rigel) is a clinical-stage drug development company that discovers and develops small molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases.
To see more analyst ratings on RIGL Click Here.
Related Categories
UpgradesStocks Mentioned
+0.18Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
